America In-Vitro Diagnostics Market: Growth, Trends, and Opportunities

 

According to Next Move Strategy Consulting, the America In-Vitro Diagnostics (IVD) Market has emerged as a key sector in the healthcare industry, driving forward the diagnostic capabilities that aid in the detection and management of diseases. the market is projected to reach USD 50 billion by 2030, reflecting a compound annual growth rate (CAGR) of 4% by 2030. The IVD market encompasses a broad range of medical devices and tests used to detect various diseases or conditions through samples like blood, urine, and tissue, thereby eliminating the need for invasive procedures.

The in-vitro diagnostics market covers numerous test types, including clinical chemistry, molecular diagnostics, immunoassays, hematology, microbiology, and coagulation. These tests employ cutting-edge technologies such as Polymerase Chain Reaction (PCR), next-generation sequencing (NGS), microarrays, mass spectrometry, and immunoassays. IVD plays an indispensable role in modern healthcare by assisting with disease diagnosis, monitoring chronic conditions, guiding treatment decisions, and screening for a wide range of diseases such as cancer, infectious diseases, cardiology-related disorders, diabetes, and genetic conditions. These diagnostics are utilized across various healthcare settings, including hospitals, outpatient clinics, and laboratories, helping clinicians make accurate, timely medical decisions.

Click Here for Your FREE Sample!

Market Growth Drivers

Increasing Prevalence of Chronic and Infectious Diseases

The growing prevalence of chronic diseases such as cardiovascular diseases, cancer, and diabetes, as well as infectious diseases, is significantly boosting the demand for diagnostic tests in the in-vitro diagnostics market across America. These conditions pose substantial public health challenges, leading to a rise in the adoption of early detection techniques, disease monitoring, and personalized treatment strategies.

As per the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), nearly 6 out of 10 adults in the U.S. are living with one or more chronic conditions. Cardiovascular diseases, cancer, and diabetes remain the leading causes of mortality in the country, driving the demand for early detection and monitoring tools offered by IVD.

Download Free Sample

Aging Population Driving Market Expansion

Another critical factor contributing to the growth of the IVD market in America is the aging population. As the elderly population grows, there is an increase in age-related diseases, necessitating more frequent diagnostic testing for early detection, ongoing monitoring, and management to prevent further complications.

According to the Pan American Health Organization, the number of elderly individuals is rapidly increasing across American countries, with Brazil standing out for its sizable older population. By 2030, it is anticipated that Brazil will have nearly 50 million individuals aged 60 years and above, further amplifying the demand for IVD solutions. Healthcare providers in the region are focused on meeting the specific healthcare needs of this demographic, fueling demand for diagnostic tools that are more accurate, timely, and tailored to individual health needs.

Challenges in Market Growth

High Costs of R&D and Regulatory Approval

Despite its promising growth trajectory, the America IVD market faces several challenges. A major restraint is the high cost associated with research and development (R&D) as well as the stringent regulatory approval processes required for IVD products. Developing reliable diagnostic technologies necessitates significant investment in clinical trials, laboratory testing, and product refinement. Moreover, the regulatory landscape, particularly in the U.S., is complex, with the Food and Drug Administration (FDA) enforcing rigorous standards for product approval. These financial and regulatory hurdles can deter new entrants into the market and limit the expansion of existing companies.

Emerging Opportunities: Point-of-Care Testing (POCT)

Point-of-care testing (POCT) is emerging as a significant opportunity within the America IVD market. This technology provides healthcare professionals with the ability to obtain rapid diagnostic results at the patient’s location, such as in emergency departments, ambulances, or remote healthcare settings. POCT is essential in situations where immediate results are crucial for effective treatment, including infectious disease testing, cardiac marker monitoring, glucose levels, and pregnancy testing.

The integration of POCT with traditional IVD methods offers a holistic approach to diagnostics, enhancing healthcare workflows, improving diagnostic accuracy, and enabling timely interventions. With the rising demand for immediate and efficient healthcare services, POCT is expected to play a critical role in shaping the future of the IVD industry.

Market Segment Analysis

Reagents Dominate the Market Share

Reagents, which account for approximately 59% of the market share in the type segment, continue to be the dominant category in the America IVD market. Reagents play a vital role in IVD testing by facilitating the detection of specific biomarkers or substances indicative of diseases or health conditions. Their versatility in accommodating different testing methodologies and platforms ensures their widespread use across various diagnostic techniques.

The ongoing rise in demand for diagnostic testing, driven by the increasing prevalence of chronic diseases and the growing elderly population, continues to support the dominance of reagents in the IVD market.

Immunodiagnostics Hold Largest Share

Immunodiagnostics are the largest segment in the technique category, comprising approximately 33% of the America IVD market. Immunodiagnostic tests offer high accuracy and sensitivity in detecting specific antigens or antibodies, making them crucial for the diagnosis of conditions such as cancer, diabetes, cardiovascular diseases, and various infections. These tests are vital for early disease detection, which is crucial for effective treatment and management.

Regional Insights: U.S. Dominates, Uruguay Shows Strong Growth Potential

The United States remains the dominant player in the America IVD market. The increasing prevalence of chronic diseases, including cardiovascular diseases, cancer, and diabetes, has significantly boosted the demand for IVD tests. Furthermore, the presence of major companies such as Bio-Rad Laboratories, Becton, Dickinson and Company, Abbott Laboratories, and Quest Diagnostics fosters market growth through continuous innovation, R&D, and partnerships.

For instance, in January 2023, Bio-Rad Laboratories launched the CFX Opus 96 Dx Real-Time PCR System, which was approved by the U.S. FDA. This new product offers healthcare professionals advanced tools to deliver precise diagnostic results and improve patient care.

Uruguay, on the other hand, is anticipated to experience the fastest growth rate in the America IVD market. The increasing prevalence of diabetes in Uruguay is a key driver of this growth. With a growing diabetic population and substantial healthcare investments, Uruguay is poised to remain at the forefront of the IVD market’s expansion in the region. As of 2021, the IDF Diabetes Atlas reported a significant rise in the number of people with diabetes in Uruguay, and this trend is expected to continue, creating a heightened demand for diagnostic testing.

Competitive Landscape

Several key players dominate the America In-Vitro Diagnostics Market, including:

• Roche Holding AG
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Becton, Dickinson and Company
• Siemens Healthineers AG
• bioMérieux SA
• Sysmex Corporation
• QIAGEN N.V.
• Bio-Rad Laboratories, Inc.

These companies are implementing strategies such as partnerships, mergers, acquisitions, and innovative product launches to strengthen their positions in the market. For instance, in February 2024, Roche Holding AG partnered with PathAI to develop AI-driven companion diagnostic tools that aim to accelerate the advancement of precision medicine.

Conclusion

The America In-Vitro Diagnostics Market is poised for significant growth, driven by the increasing prevalence of chronic and infectious diseases, the aging population, and the continued need for advanced diagnostic technologies. Although challenges related to high R&D and regulatory costs persist, opportunities such as Point-of-Care Testing (POCT) and the dominance of reagents and immunodiagnostic tests are expected to shape the market’s future trajectory. With continued technological advancements and strategic investments by key industry players, the America IVD market is expected to witness sustained growth in the coming years.

About Next Move Strategy Consulting:

Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations within dustry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses

Summary

Challenges include high costs associated with research, development, and regulatory approval, which can limit market expansion. However, Point-of-Care Testing (POCT) is an emerging opportunity, offering rapid diagnostics in critical care settings. Reagents and immunodiagnostic techniques dominate the market, with immunodiagnostics holding a 33% share due to their accuracy and sensitivity.